

ResApp secures contract with global pharmaceutical company

- ResApp has signed a licensing agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to use ResAppDx technology in an RSV clinical trial
- First time ResAppDx will be used by a third party to monitor patients in a clinical trial setting
- Agreement is a further validation of ResApp's technology with global data

Brisbane, Australia, 18 November 2021 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that it has secured a three year, non-exclusive licensing agreement with Janssen Pharmaceutica NV (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the use of its ResAppDx technology in a respiratory syncytial virus (RSV) clinical trial. This agreement was facilitated by Johnson & Johnson Innovation. ResApp was awarded the AusBiotech and Johnson & Johnson Innovation Industry Excellence Award for Emerging Company of the Year in 2016.

ResAppDx will be used in a clinical trial conducted by Janssen to assess the respiratory symptoms of a cohort of patients with a range of respiratory diseases, including RSV. In adults, RSV symptoms are typically mild and similar to the common cold, however in severe cases RSV can spread to the lower respiratory tract causing pneumonia or acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD) or asthma. The trial will be conducted in the United States, Europe, South America and Asia-Pacific, and is expected to commence later this calendar year. Janssen will pay development and maintenance costs in addition to a fee per ResAppDx test to ResApp.

ResApp Health CEO and Managing Director, Dr Tony Keating said: *"Almost 160,000 people die each year worldwide as a consequence of RSV. ResApp Health is proud to be supporting Janssen in further understanding the impact of this disease on individual patients, which may help to inform prevention and treatment strategies."*

"With this agreement, we are demonstrating that leading global pharmaceutical companies see the value of ResAppDx in a clinical trial setting. While not expected to have a material impact on our operating results at this stage, this contract represents the beginning of our commercial relationship with Janssen and will further build the body of high quality, clinical evidence regarding the use of ResAppDx."

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, an at-home sleep apnoea screening app for consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Contacts for ResApp Health

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.